Efficacy and Prognostic Factors of Docetaxel Combined with ADT on Metastatic Hormone-sensitive Prostate Cancer Patients

• Main Authors: LIU Sanhe, CUI Diansheng, JIA Quan'an, Duan Liqun, DENG Kangli, HUANG Lei, WEI Shaozhong
• Format: Article
• Language: zho
• Published: Magazine House of Cancer Research on Prevention and Treatment 2019-06-01
• Series: Zhongliu Fangzhi Yanjiu
• Subjects: docetaxel; adt; metastatic hormone-sensitive prostate cancer; efficacy; prognostic factor
• Online Access: http://html.rhhz.net/ZLFZYJ/html/8578.2019.19.0051.htm

Objective To assess the efficacy of docetaxel plus ADT on mHSPC patients and analyze the prognostic factors. Methods We retrospectively reviewed the clinical data of 107 mHSPC patients treated with docetaxel plus ADT. Co-primary end points were PSA PFS and rPFS. Univariable and multivariable Cox analyses were performed to determine prognostic factors for PSA PFS and rPFS. Results The median follow-up time was 36 months, and 13 (12.1%) patients died. The median PSA PFS and rPFS were 34.000 (30.878-37.122) and 33.000 (30.031-35.969) months, respectively. Univariate analysis results showed that the serum PSA, PSA nadir at 7th month (≤0.2ng/dl vs. > 0.2ng/dl), number of chemotherapy cycles (≤6 vs. 7-12), ECOG PS (0-1 vs. 2) and visceral disease (yes vs. no) were independent predictors for PSA PFS and rPFS. Multivariate analysis results showed that PSA nadir at 7th month (≤0.2ng/dl vs. > 0.2ng/dl) and visceral disease (yes vs. no) were independent predictors for PSA PFS and rPFS. Conclusion The effect of docetaxel plus ADT on patients with mHSPC in China is favorable. PSA nadir at 7th month (≤0.2ng/dl vs. > 0.2ng/dl) and visceral disease (yes vs. no) are independent predictors for PSA PFS and rPFS.